BKBasil Künnecke

Basil Künnecke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Basil Künnecke has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hyperactivation of distinct thalamic nuclei differentially impairs sleep physiology in rats

    by Joana Mendes Duarte, Philipp Janz, Andreas Bruns, Simon Gross, Marie Bainier, Sébastien Debilly, Stephanie Schöppenthau, Thomas Bielser, Basil Künnecke, Jan M. Schulz, et al.

    Sleep disturbances and altered sensory processing are key features of neurodevelopmental and neuropsychiatric disorders (NDDs/NPDs). Clinical assessments of brain function in these conditions reveal increased connectivity between the thalamus and cortical areas, alongside changes in restorative sleep patterns that rely on thalamic function, like decreased sleep spindle density and slow-wave oscillations. To assess the role of individual thalamic nuclei in such impairments, we activated thalamic nuclei within three different thalamocortical circuits in rats using the chemogenetic receptor hM3Dq. Activation of the mediodorsal thalamic (MDT) nuclei impaired restorative sleep by reducing spindle density and slow-wave oscillations, recapitulating phenotypes associated with NDDs/NPDs. Conversely, activating ventral posterior thalamic (VPT) and ventromedial thalamic (VMT) nuclei increased wakefulness, reducing sleep spindle density and alpha/beta band power during sleep. To examine downstream network effects, we used perfusion-based pharmacological MRI; MDT activation significantly modulated neural activity in MDT and interconnected regions, including prelimbic cortex and thalamic nuclei. Finally, we tested whether pharmacologically increasing inhibition in the thalamus using the GABAAδ agonist gaboxadol and positive allosteric modulator DS-2, could counter phenotypes driven by thalamic hyperactivity. Gaboxadol partially normalized the balance between light and deep NREM sleep in the MDT-hM3Dq group, and in VPT- and VMT-hM3Dq animals, partially normalized resting-state oscillations but failed to rescue sleep physiology. DS-2 had minimal effects across groups. Collectively, our findings reveal that thalamic nuclei-specific activation impacts restorative sleep, and that this thalamocortical circuit model may provide valuable insights into the neural mechanisms underlying dysfunctions associated with NDDs/NPDs and neuropsychiatric conditions.


  • Novel selective morpholine trace amine-associated receptor 1 partial agonists show promising preclinical effects for neuropsychiatric disorders and are well tolerated in healthy volunteers

    by Céline Fournier, Danièle Buchy, Susanne Mohr, Axel Pähler, Bjoern Jacobsen, Roger Norcross, Philippe Pflieger, Sabine Sewing, Andrea Greiter-Wilke, Basil Kuennecke, et al.

    Trace amine-associated receptor 1 (TAAR1) is a novel target for antipsychotic and potentially mood-stabilizing and anti-addictive drugs, offering a new mechanism by modulating dopaminergic, serotonergic, and glutamatergic neurotransmission. TAAR1 agonists from a prior amino oxazolines series were studied preclinically and clinically, but development of partial agonist RO5263397 was halted due to poor metabolization by N-glucuronidation in individuals with UGT2B10 splice site mutations. A medicinal chemistry program subsequently identified new potent and selective TAAR1 ligands from the morpholine series. Two selective partial agonists, RO6799477 and RO6889450, were advanced and showed antipsychotic, stress-response-modulating, and anti-addictive-like activity in rodent models. They reduced PCP- and cocaine-induced hyperlocomotion, potentiated olanzapine’s effect, partially reversed cocaine-induced facilitation of intracranial self-stimulation and demonstrated anxiolytic-like properties in the stress-induced hyperthermia test. Neural activation profiles, measured by pharmacological MRI, differed from first and second-generation antipsychotics. Non-clinical drug abuse liability studies with RO6889450 indicated a favorable low abuse liability profile and suggested a lack of reinforcing effects. Preclinical safety studies indicated a favorable profile with clinically monitorable and reversible findings. Both compounds progressed into Phase I single and multiple ascending dose studies in healthy volunteers. RO6799477 was well tolerated, with rapid absorption and dose-proportional pharmacokinetics, though higher doses led to nervous system and cardiovascular adverse events. RO6889450 was well tolerated up to 300 mg; at 450 mg, dose-limiting adverse events included postural tachycardia and erythema. Together, these results indicate the translational potential and support further clinical exploration of TAAR1 agonists as a novel therapeutic option for neuropsychiatric disorders, particularly schizophrenia and substance use disorder.


  • Open Access

    Hyperactivation of distinct thalamic nuclei differentially impairs sleep physiology in rats

    by Roger Redondo, Joana Mendes Duarte, Philipp Janz, Andreas Bruns, Simon Gross, Marie Bainier, Sébastien Debilly, Stephanie Schöppenthau, Thomas Bielser, Basil Kuennecke, et al.

    Sleep disturbances and altered sensory processing are key features of neurodevelopmental and neuropsychiatric disorders (NDDs/NPDs). Clinical assessments of brain function in these conditions reveal increased connectivity between the thalamus and cortical areas, alongside changes in restorative sleep patterns that rely on thalamic function, like decreased sleep spindle density and slow-wave oscillations. To assess the role of individual thalamic nuclei in such impairments, we activated thalamic nuclei within three different thalamocortical circuits in rats using the chemogenetic receptor hM3Dq. Activation of the mediodorsal thalamic (MDT) nuclei impaired restorative sleep by reducing spindle density and slow-wave oscillations, recapitulating phenotypes associated with NDDs/NPDs. Conversely, activating ventral posterior thalamic (VPT) and ventromedial thalamic (VMT) nuclei increased wakefulness, reducing sleep spindle density and alpha/beta band power during sleep. To examine downstream network effects, we used perfusion-based pharmacological MRI; MDT activation significantly modulated neural activity in MDT and interconnected regions, including prelimbic cortex and thalamic nuclei. Finally, we tested whether pharmacologically increasing inhibition in the thalamus using the GABAAδ agonist gaboxadol and positive allosteric modulator DS-2, could counter phenotypes driven by thalamic hyperactivity. Gaboxadol normalized the balance between light and deep NREM sleep in the MDT-hM3Dq group, and in VPT- and VMT-hM3Dq animals, partially normalized resting-state oscillations but failed to rescue sleep physiology. DS-2 had minimal effects across groups. Collectively, our findings reveal that thalamic nuclei-specific activation impacts restorative sleep, and that this thalamocortical circuit model may provide valuable insights into the neural mechanisms underlying dysfunctions associated with NDDs/NPDs and neuropsychiatric conditions.


  • Open Access

    Deep learning applied to the segmentation of rodent brain MRI data outperforms noisy ground truth on full-fledged brain atlases

    by Jonas Kohler, Thomas Bielser, Stanislaw Adaszewski, Basil Künnecke, Andreas Bruns


  • Neuropharmacological and Neurobiological Relevance of In vivo 1H-MRS of GABA and Glutamate for Preclinical Drug Discovery in Mental Disorders

    by Conny F Waschkies, Andreas Bruns, Stephan Müller, Martin Kapps, Edilio Borroni, Markus von Kienlin, Markus Rudin, Basil Künnecke

    Proton magnetic resonance spectroscopy ((1)H-magnetic resonance spectroscopy (MRS)) is a translational modality with great appeal for neuroscience since the two major excitatory and inhibitory neurotransmitters, glutamate, and GABA, can be noninvasively quantified in vivo and have served to explore disease state and effects of drug treatment. Yet, if (1)H-MRS shall serve for decision making in preclinical pharmaceutical drug discovery, it has to meet stringent requirements. In particular, (1)H-MRS needs to reliably report neurobiologically relevant but rather small changes in neurometabolite levels upon pharmacological interventions and to faithfully appraise target engagement in the associated molecular pathways at pharmacologically relevant doses. Here, we thoroughly addressed these matters with a three-pronged approach. Firstly, we determined the sensitivity and reproducibility of (1)H-MRS in rat at 9.4 Tesla for detecting changes in GABA and glutamate levels in the striatum and the prefrontal cortex, respectively. Secondly, we evaluated the neuropharmacological and neurobiological relevance of the MRS readouts by pharmacological interventions with five well-characterized drugs (vigabatrin, 3-mercaptopropionate, tiagabine, methionine sulfoximine, and riluzole), which target key nodes in GABAergic and glutamatergic neurotransmission. Finally, we corroborated the MRS findings with ex vivo biochemical analyses of drug exposure and neurometabolite concentrations. For all five interventions tested, (1)H-MRS provided distinct drug dose-effect relationships in GABA and glutamate over preclinically relevant dose ranges and changes as low as 6% in glutamate and 12% in GABA were reliably detected from 16 mm(3) volumes-of-interest. Taken together, these findings demonstrate the value and limitation of quantitative (1)H-MRS of glutamate and GABA for preclinical pharmaceutical research in mental disorders.


  • Neuroimaging Endophenotypes in Animal Models of Autism Spectrum Disorders: Lost or Found in Translation?

    by Marija M. Petrinovic, Basil Künnecke

    Autism spectrum disorder(s) (ASDs) is a neurodevelopmental disorder characterized by stereotyped behaviours and impairments in communication and social interactions. This heterogeneity has been a major obstacle in uncovering the aetiology and biomarkers of ASDs. Rodent models with genetic modifications or environmental insults have been created to study particular endophenotypes and bridge the gap between genetics and behavioural phenotypes. Translational neuroimaging modalities with their ability to screen the brain noninvasively and yield structural, biochemical and functional information provide a unique platform for discovery and evaluation of such endophenotypes in preclinical and clinical research.


  • Validation of cerebral blood perfusion imaging as a modality for quantitative pharmacological MRI in rats

    by Andreas Bruns, Basil Künnecke, Céline Risterucci, Jean‐Luc Moreau, Markus von Kienlin

    The aim of this study was to validate continuous arterial spin labeling (CASL) as a quantitative imaging modality for pharmacological MRI (phMRI) based on local cerebral blood perfusion. Specifically, the capability of CASL to assess brain‐activity signatures of pharmacological interventions in animal models was evaluated with respect to drug discovery in diseases of the central nervous system (CNS). Perfusion as a surrogate for neuronal activity was measured in various brain areas of the rat. The validation approach was threefold. First, perfusion was shown to reliably reflect differential effects of anesthesia on striatal activation. Different baseline levels and different temporal response profiles after amphetamine challenges under isoflurane, propofol, ketamine, and α‐chloralose anesthesia were consistent with known properties of these anesthetics. Second, remarkable consistency of multi‐area baseline perfusion patterns between independent groups of animals confirmed the notion that CASL is highly reproducible and thus particularly suitable for long‐term longitudinal studies. Third, administration of the well‐characterized psychotomimetic compounds amphetamine and phencyclidine (PCP) elicited dose‐dependent activation patterns that were related to the drugs' particular interactions with the dopaminergic and glutamatergic systems, respectively. In conclusion, perfusion‐based phMRI is a robust, reliable and valid quantitative technique suitable for evaluating brain‐activation patterns in animal models of CNS diseases. Magn Reson Med, 2009.


  • Quantitative Body Composition Analysis in Awake Mice and Rats by Magnetic Resonance Relaxometry

    by Basil Künnecke, Philippe Verry, Agnès Bénardeau, Markus Von Kienlin

    Objective: Magnetic resonance (MR) relaxometry has recently been introduced for noninvasive body composition analysis in awake mice. The purpose of the present study was to extend the method to rats and to introduce calibration procedures that render MR relaxometry fully quantitative.Research Methods and Procedures: Proton T2 MR relaxometry at 4.7 Tesla was used for body composition analyses in 700 awake mice and 400 rats of different strains and conditions. Relaxograms calculated from the signal decays observed with multi‐spin‐echo acquisition provided well‐separated contributions of tissue water and fat. Analysis of fat composition was carried out in vivo using 13C‐MR spectroscopy. Evolution of body composition in rats was assessed during drug treatment.Results: MR relaxometry for noninvasive body composition analysis in laboratory rodents was implemented on a standard MR scanner, and a throughput of >30 animals per hour was achieved. Excellent linearity and reproducibility with coefficients of variance as low as 2.5% and 1.7% were obtained in mice and rats, respectively. The lean mass‐to‐water ratio (mice, 1.35 ± 0.03; rats, 1.39 ± 0.04) and the proton density of fat (mice, 8.1 ± 0.2; rats, 8.9 ± 0.2 g/mol) were determined from cross‐sectional data. Fat composition analysis by 13C‐MR spectroscopy corroborated these findings and yielded information on the average acyl chain length (16.3 ± 1.6) and contributions of saturated (27 ± 3%), monounsaturated (22 ± 2%), and polyunsaturated (51 ± 3%) fatty acids. Longitudinal assessments in rats treated with sibutramine and dexfenfluramine showed dose‐related changes in body composition.Discussion: T2 MR relaxometry backed by solid calibration provides a powerful means for rapid quantitative body composition analysis in awake mice and rats that is suitable for serial investigations in pharmaceutical research.